Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Phone+1-617-9969058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.01. The firm had revenue of $0.89 million for the quarter, compared to analysts' expectations of $0.70 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 brokers have issued 12-month price objectives for Myomo's stock. Their predictions range from $7.00 to $12.00. On average, they anticipate Myomo's share price to reach $9.50 in the next year. This suggests a possible upside of 660.0% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
Media coverage about MYO stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myomo earned a news impact score of 1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Are investors shorting Myomo?
Myomo saw a drop in short interest in the month of February. As of February 15th, there was short interest totalling 508,055 shares, a drop of 6.8% from the January 31st total of 545,305 shares. Based on an average daily trading volume, of 137,507 shares, the days-to-cover ratio is presently 3.7 days. Approximately 5.0% of the shares of the company are short sold. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Protech Home Medical (PHM), Electromed (ELMD), Osprey Medical (OSP), Avacta Group (AVCT), Universal Biosensors (UBI), Resonance Health (RHT), Oventus Medical (OVN), Viveve Medical (VIVE), Surgical Innovations Group (SUN), EMvision Medical Devices (EMV), Anteo Diagnostics (ADO), Inspiration Healthcare Group (IHC), GI Dynamics (GID), Polarean Imaging (POLX) and Rewalk Robotics (RWLK).
What other stocks do shareholders of Myomo own?
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 64)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 65)
- Mr. Jonathan Naft, VP & GM (Age 54)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 71)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 69)
Who are Myomo's major shareholders?
Myomo's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.38%).
Which major investors are buying Myomo stock?
MYO stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp.
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $1.25.
How big of a company is Myomo?
Myomo has a market capitalization of $15.54 million.
What is Myomo's official website?
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
